Sharekhan has given Buy recommendation for Cadila Healthcare with a target price of Rs. 720 in its research report issued on May 27, 2021
Sharekhan’s research report on Cadila Healthcare
Cadila Healthcare’s (Cadila) Q4FY2021 numbers were healthy and earnings beat estimates, due to a tax credit and an adjustment for a one-time impairment expenses. Cadila is in a sweet spot, wherein both its geographies, India and the US have an improved growth outlook. Efforts to build a portfolio of Covid drugs including Vaccines augurs well from a growth perspective.
Outlook
We retain our Buy recommendation on the stock with unchanged PT of Rs. 720